International Journal of Endocrinology / 2017 / Article / Tab 3

Research Article

Pretreatment BMI Is Associated with Aggressive Clinicopathological Features of Papillary Thyroid Carcinoma: A Multicenter Study

Table 3

Risk of aggressiveness clinicopathological features in patients with papillary thyroid cancer according to BMI group.

BMI at diagnosis (kg/m2)
BMI < 18.5
18.5 ≤ BMI < 23
23 ≤ BMI < 27.5
BMI ≥ 27.5

Primary tumor size ≥1 cm
Number of patients (%)30 (38.46%)340 (41.16%)147 (35.5%)148 (48.68%)
OR (95% CI)0.90 (0.56–1.44)Reference0.79 (0.59–1.06)1.33 (0.90–1.98)
value0.370.070.10
Extrathyroidal extension
Number of patients (%)27 (34.62%)287 (34.75%)170 (41.06%)141 (46.38%)
OR (95% CI)0.99 (0.61–1.60)Reference1.32 (0.98–1.76)1.61 (1.08–2.4)
value0.540.040.01
Multifocality
Number of patients (%)24 (30.77%)263 (31.84%)167 (40.34%)129 (42.43%)
OR (95% CI)0.95 (0.58–1.56)Reference1.45 (1.08–1.94)1.58 (1.05–2.36)
value0.480.0090.02
Cervical lymph node metastasis
Number of patients (%)28 (35.9%)314 (38.01%)163 (39.37%)149 (49.01%)
OR (95% CI)0.91 (0.57–1.47)Reference1.06 (0.79–1.42)1.57 (1.06–2.34)
value0.400.370.02
Distant metastasis
Number of patients (%)3 (3.85%)14 (1.69%)11 (2.68%)2 (1.89%)
OR (95% CI)2.27 (0.66–7.79)Reference1.57 (0.63–3.94)1.09 (0.25–4.73)
value0.170.230.57
Advanced TNM stage
Number of patients (%)29 (37.18%)301 (36.44%)189 (45.65%)154 (50.66%)
OR (95% CI)1.03 (0.64–1.66)Reference1.47 (1.10–1.96)1.81 (1.23–2.70)
value0.500.0060.002

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.